

December 9, 2021

Joseph Hernandez
Chief Executive Officer
Blue Water Vaccines Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202

Inc.

Registration Statement on Form S-1
2021

Re: Blue Water Vaccines
Amendment No. 2 to
Filed November 29,
File No. 333-260137

Dear Mr. Hernandez:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our November 18, 2021 letter.

Amendment No. 2 to Form S-1

Our Vaccine Program, page 82

1. We note your responses to both prior comment 3 and to the first bullet in comment 6 issued in the staff's letter dated November 4, 2021. We reissue such comments and reiterate that there are still numerous instances throughout the prospectus, specifically from pages 86-101, where information presented in your tables and figures appears to be printed in much smaller type than the surrounding text. Even with enhanced pixilation, such text is not easily legible. Revise the formatting in your graphics to use a font size that is clearly readable without the need for magnification.

Participation in this Offering, page 146

Joseph Hernandez
Blue Water Vaccines Inc.
December 9, 2021
Page 2

2. We note your disclosure on the cover page and here that certain existing stockholders and their affiliates have indicated an interest to purchase up to a specific amount of common stock in the offering at the initial public offering price. We also note your disclosure that such stockholders may decide to purchase more than the amount for which they indicated an interest in buying. We have the following comments:

With reference to Item 501 of Regulation S-K, please tell us how you determined that such potential purchase information is so significant to an investment decision that it

should be referenced on the prospectus cover page.

In the new section on page 146, please identify the existing stockholders and their affiliated entities, other than Great American Insurance Company, that have indicated an interest in purchasing securities in this offering. Also tell us the aggregate dollar amount or the number of offered securities that each stockholder or affiliated entity has indicated an interest in purchasing.

So that investors will be able to understand the minimum amount of your shares that will enter the public market through sales to the public, as opposed to the existing stockholders, please disclose in the new section on page 146 whether there is a ceiling on the amount that may be purchased by existing stockholders and quantify any ceiling. If not, please disclose the potential material impact on public investors.

If the existing stockholders and/or their affiliated entities are reflected in the beneficial ownership table on page 145, please disclose under the Principal Stockholders section the expected percentage ownership if the stockholder does

purchase common stock in this offering as their indication of interest reflects. Additionally, please tell us whether these indications of interest could result in a stockholder that is not currently included in the table on page 145 beneficially owning more than 5% of your outstanding shares following the offering.

We note your disclosure that any of the existing stockholders or their affiliates that have indicated an interest in buying shares in the offering may determine to purchase more, fewer or no shares in this offering. If material, please revise your risk factors to describe how such developments would relate to the offering. In this regard, we note the risk factor on page 53 describing the concentration of stock ownership by your principal stockholders and management of the company.

Item 16. Exhibits and Financial Statement Schedules, page II-3

3. We note that your exhibit index key to Amendment No. 2 has been revised to indicate that Exhibit 24.1, Power of Attorney, was "previously filed." In this regard, it appears your

POA was included on the signature page of your S-1 filed on October 8, 2021. As applicable in your next amendment, please revise your index key to include a reference to the part of the registration statement containing the power of attorney. Refer to Item

Comapany NameBlue
601(b)(24) Water Vaccines
of Regulation S-K. Inc.

December 9, 2021 Page 2

FirstName LastName

Joseph Hernandez

FirstName

Blue WaterLastNameJoseph
Vaccines Inc. Hernandez

Comapany9,

December NameBlue

2021 Water Vaccines Inc.

December

Page 3 9, 2021 Page 3

FirstName LastName

You may contact Tara Harkins at 202-551-3639 or Mary Mast at 202-551-3613 if you

have questions regarding comments on the financial statements and related matters. Please

contact Lauren Hamill at 303-844-1008 or Celeste Murphy at 202-551-3257 with any other questions.

Corporation Finance
Sciences
cc: Jessica Yuan

Sincerely,
Division of
Office of Life